ORMP Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc. (ORMP) is expected to report earnings on November 9, 2026, before the market open. The consensus earnings estimate is $0.52 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +3.9% since its last earnings release on August 10, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals, Inc. is a pharmaceutical company operating as a developer of oral drug delivery systems. The Company is developing orally ingestible insulin capsules for the treatment of diabetes as well as delivery solutions for other drugs and vaccines. Oramed Pharmaceuticals, Inc. is headquartered in Jerusalem, Israel.
Sector
Healthcare
Industry
Drug Delivery